

**Table 2**  
Multivariate analysis for overall survival.

Covariates	HR	95% CI	p-Value
Early tumor regression (yes versus no)	0.098	0.036–0.269	<b>&lt;0.001</b>
Age (>70 versus ≤70)	1.145	0.392–3.351	0.804
Gender (male versus female)	0.000	0.000–9.509	0.965
PS (0 versus 1 or worse)	0.403	0.159–1.019	0.055
Smoking status (>600 versus ≤600)	0.160	0.035–0.737	0.019
Timing of irradiation (concurrent versus sequential)	0.379	0.105–1.371	0.139
Best overall response (CR versus PR)	0.332	0.118–0.936	<b>0.037</b>

If at least a 30% decrease in the sum of the longest diameter of target lesions was observed just before the initiation of the second cycle, we defined it as early tumor regression. Abbreviations: PS: performance status, HR: hazard ratio, CI: confidential interval, CR: complete response, PR: partial response. Bold values are statistically significant.

**Table 3**  
Multivariate analysis for progression free survival.

Covariates	HR	95% CI	p-Value
Early tumor regression (yes versus no)	0.345	0.169–0.700	<b>0.003</b>
Age (>70 versus ≤70)	0.767	0.374–1.574	0.469
Gender (male versus female)	0.347	0.083–1.446	0.146
PS (0 versus 1 or worse)	0.530	0.255–1.103	0.090
Smoking status (>600 versus ≤600)	0.485	0.163–1.444	0.194
Timing of irradiation (concurrent versus sequential)	0.747	0.302–1.850	0.528
Best overall response (CR versus PR)	0.507	0.228–1.124	0.094

If at least a 30% decrease in the sum of the longest diameter of target lesions was observed just before the initiation of the second cycle, we defined it as early tumor regression. Abbreviations: PS: performance status, HR: hazard ratio, CI: confidential interval, CR: complete response, PR: partial response. Bold values are statistically significant.

Objective response rate and MST of 97% and 20.2 months, respectively [17]. The trial results would indicate the benefit of early switch of the etoposide to the irinotecan. Based on all these findings, especially those without early tumor regression would potentially benefit most from such type of switching therapy, although further investigations are strongly needed.

We have several limitations here mainly because all the analyses were performed retrospectively using a small cohort. Also, the treatment regimens were heterogeneous, especially including both concurrent and sequential chemoradiotherapy altogether. Although several factors were adjusted in the multivariate analysis, such issues may have potentially confounded or biased our main results that should be cautiously interpreted.

5. Conclusion

Patients without early tumor regression had a poorer outcome even though they subsequently obtained confirmed objective response throughout the treatment course of the platin-based CHRT. It suggests the development of more effective treatments for these high-risk patients is needed to improve their poor prognosis. Although our study results have several limitations described above, our current findings raise important issues that should be addressed in future studies.

Conflicts of interest

Dr. Hotta was paid an honorarium for lecturing from Sanofi-Aventis Japan, Nihon Kayaku, Lilly Japan and Chugai pharmaceutical. Drs. Takigawa and Kiura were paid an honorarium for lecturing from Sanofi-Aventis and Chugai pharmaceutical, Japan. The other authors report no conflict of interest.

Funding

None declared.

References

[1] Sagman U, Maki E, Evans WK, Warr D, Shepherd FA, Sculier JP, et al. Small-cell carcinoma of the lung: derivation of a prognostic staging system. *J Clin Oncol* 1991;9:1639.

[2] Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinant of improved outcome in small-cell lung cancer: an analysis of the 2580-patient Southwest Oncology Group database. *J Clin Oncol* 1990;8:1563.

[3] Stupp R, Monnerat C, Turrisi 3rd AT, Perry MC, Leyvraz S. Small cell lung cancer: state of the art and future perspectives. *Lung Cancer* 2004;45: 105–17.

[4] Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. *PLoS One* 2009;4:e7835.

[5] Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. *J Clin Oncol* 1992;10:890–5.

[6] Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. *J Thorac Oncol* 2009;4:311–7.

[7] Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. *J Clin Oncol* 2005;23:5117–25.

[8] Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Harita S, et al. Continued gefitinib treatment after disease stabilization prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. *Ann Oncol* 2005;16:1817–23.

[9] Hotta K, Kiura K, Fujiwara Y, Takigawa N, Oze I, Ochi N, et al. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. *Ann Oncol* 2009;20:829–34.

[10] Turrisi 3rd AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice daily compared with thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med* 1999;340:265–71.

[11] Sirohi B, Ashley S, Norton A, Popat S, Hughes S, Papadopoulos P, et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. *J Thorac Oncol* 2007;2:735–40.

[12] Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. *J Clin Oncol* 2002;20:3054–60.

[13] Ueoka H, Kiura K, Tabata M, Kamei H, Gemba K, Sakae K, et al. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma. *Cancer* 1998;83:283–90.

[14] Kurup A, Hanna NH. Treatment of small cell lung cancer. *Crit Rev Oncol Hematol* 2004;52:117–26.

- [15] Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. *J Clin Oncol* 2005;23:3488–94.
- [16] Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guideline to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institutes of Canada. *J Natl Cancer Inst* 2000;92:205–16.
- [17] Kubota K, Nishiwaki Y, Sugiura T, Noda K, Mori K, Kawahara M, et al. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. *Clin Cancer Res* 2005;11:5534–8.

## Cytotoxicity of Activated Natural Killer Cells and Expression of Adhesion Molecules in Small-cell Lung Cancer

TADASHI TSUCHIDA<sup>1</sup>, HIROMICHI YAMANE<sup>2</sup>, NOBUAKI OCHI<sup>2</sup>, TAKAYUKI TABAYASHI<sup>2</sup>, AKIO HIRAKI<sup>1</sup>,  
NAOYUKI NOGAMI<sup>1</sup>, NAGIO TAKIGAWA<sup>2</sup>, KATSUYUKI KIURA<sup>3</sup> and MITSUNE TANIMOTO<sup>1</sup>

<sup>1</sup>Department of Hematology, Oncology, and Respiratory Medicine,  
Okayama University Graduate School of Medicine, Kita-ku, Okayama, Japan;

<sup>2</sup>Department of General Internal Medicine 4, Kawasaki Medical School, Kita-ku, Okayama, Japan;

<sup>3</sup>Department of Respiratory Medicine, Okayama University Hospital, Kita-ku, Okayama Japan

**Abstract.** *Background/Aim:* Although small-cell lung cancer (SCLC) is sensitive to anticancer agents, most patients with SCLC experience relapse and die within two years. Here, we examined the relationship between natural killer (NK) cells and adhesion molecules on SCLC cell lines. *Materials and Methods:* The expression levels of HLA class I,  $\beta$ 2-microglobulin, Fas/Apo-1 receptor (FAS) and adhesion molecules on SCLC cell lines were examined by flow cytometry. The cytotoxicity of activated NK cells from SCLC patients was examined using <sup>51</sup>Cr-release assay. *Results:* HLA class I antigen and  $\beta$ 2-microglobulin expression levels in SCLC cell lines were lower than those in healthy volunteers. SCLC cell lines were susceptible to lysis by activated NK cells but this showed no correlation with expression levels of adhesion molecules. *Conclusion:* Target cell susceptibility to activated NK cells from five SCLC patients correlated with survival benefit; target cell susceptibility to activated NK cells may be a surrogate marker of outcome for patients with SCLC.

Lung cancer is the leading cause of cancer mortality in Japan and the majority of industrialized countries. While its incidence has decreased in the US, lung cancer is still increasing in many developing countries (1). Small-cell lung cancer (SCLC) is one of the solid tumors most sensitive to anticancer agents. Generally, platinum-based chemotherapy including etoposide or irinotecan is the mainstay of first-line treatment for SCLC. The objective response rate for SCLC

with recent chemotherapy combinations exceeds 50%, even in patients with extensive disease, in Western countries (2). Despite high initial response rates, most patients eventually experience disease relapse. Except for topotecan and amrubicin, few treatment options remain after relapse (3, 4). Clinical trials of high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AH SCT) showed that progression-free survival could be improved in patients with limited SCLC and in a few patients with extensive SCLC about a decade ago (5, 6); however, these positive results obtained in phase II clinical trials with high-dose chemotherapy were not confirmed in large-scale phase III trials. The SCLC chemotherapy status has not changed for 15 years, despite marked progress in molecular targeted therapy based on oncogenic driver mutation in non-SCLC (7). Accordingly, new approaches to improve SCLC treatment outcomes are needed. A meta-analysis of published randomized clinical trials involving maintenance therapy following systemic chemotherapy using cytokines showed no survival advantage (8). These results suggest that maintenance and/or the consolidation approach using interferons and other biological agents failed to improve SCLC outcomes. In an effort to investigate the possibility of an immunological approach using natural killer (NK) cells, we performed experiments to clarify the relationship between NK cell activity and adhesion molecules on SCLC cell lines.

### Materials and Methods

*Patients' characteristics.* Table I shows the characteristics of our study population. All patients were diagnosed with SCLC pathologically and treated with standard- or high-dose chemotherapy with AH SCT. Disease stage was determined according to the UICC Manual of Clinical Oncology (9). All patients obtained a complete response. Performance status ranged from 0 to 4, with various clinical stages. Written informed consent concerning this study was obtained from all patients prior to treatment.

*Correspondence to:* Hiromichi Yamane, MD, Ph.D., Department of General Internal Medicine 4, Kawasaki Medical School, 2-1-80 Nakasange, Kita-ku, Okayama 700-8505, Japan. Tel: +81 862252111, Fax: +81 862328343, e-mail: hiromichi.ya@gmail.com

**Key Words:** Natural killer cell, target cell susceptibility, HLA-class I, small-cell lung cancer, adhesion molecules.

Table I. Characteristics of patients with small-cell lung cancer participating in this study.

Patient	Age (years)/Gender	PS	TNM	Stage	Treatment	Survival (years)	Relapse
1	53/M	4	T3N2M1	IV ED	HD-ICE	1.5	+
2	58/M	1	T4N3M0	IIIB LD	CT	3.4	+
3	75/M	0	T1N1M0	II LD	CT	0.8	+
4	50/M	1	T2N2M0	IIIA LD	CT	4.1	-
5	65/M	1	T4N2M0	IIIA LD	HD-ICE	4.5	-

ED, Extensive disease; LD, limited disease; PS, performance status; HDICE, high-dose chemotherapy (ifosfamide/carboplatin/etoposide) with autologous hematopoietic stem cell transplantation; CT, standard chemotherapy or chemoradiotherapy; TNM, tumor node metastasis.

Table II. Characteristics of small-cell lung cancer cell lines.

Cell line	Growth characteristic	Disease extent at diagnosis	Site of primary culture and disease status
SBC-1	Floating aggregates	T4N1M0, LD	Pleural effusion at PD
SBC-2	Loosely adherent	T2N2M1, ED	Bone marrow at PD
SBC-3	Loosely adherent	T3N2M1, ED	Bone marrow before treatment
SBC-4	Loosely adherent	T2N1M1, ED	Bone marrow at PD
SBC-5	Loosely adherent	T4N2M1, ED	Pleural effusion at PD
SBC-6	Loosely adherent	T1N2M1, ED	Pleural effusion at PD
SBC-7	Floating aggregates	T1N3M1, ED	Pericardial effusion at PD
SBC-9A	Floating aggregates	T2N2M1, ED	Pericardial effusion at PD
Lu-134-AH	Floating aggregates	Not reported	Primary lung tumor
NCI-H69	Floating aggregates	Not reported	Not reported
RERF-LC-FM	Floating aggregates	Not reported	Not reported

ED, Extensive disease; LD, limited disease; PD, progressive disease.

**Cell lines.** Table II summarizes the characteristics of 10 human SCLC lines examined in this study. SBC-1 (JCRB0816), SBC-2 (JCRB0817), SBC-3 (JCRB0818), SBC-4, SBC-5 (JCRB0819), SBC-6, SBC-7, SBC-9A (SCLC), EBC-2 (non-SCLC), and OU-LC-AS1 (non-SCLC) were established in our laboratories (10, 11). Lu-134-A-H (JCRB0235), RERF-LC-FM (JCRB0102), K562 (JCRB0019, a cell line from blast crisis of chronic myeloid leukemia), and a control NK-sensitive cell line were provided by the Japanese Cancer Research Resources Bank (Tokyo, Japan). NCI-H69 was purchased from the American Type Culture Collection (Rockville, MD, USA). All cell lines were maintained in tissue culture flasks at 37°C under a humidified atmosphere supplemented with 5% CO<sub>2</sub> in air. The culture medium used in this study was RPMI-1640 (Life Technologies, Inc., Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (ICN Biomedicals Japan Co., Ltd., Tokyo, Japan), penicillin-G (100 U/ml), and streptomycin (100 µg/ml).

**Antibodies.** Monoclonal antibodies (mAbs) used in this study were as follows: fluorescein isothiocyanate (FITC)-conjugated anti-human HLA class I antigen mAb (clone Tu149, mouse IgG<sub>2a</sub>) from Caltag Laboratories Inc. (Burlingame, CA, USA); phycoerythrin(PE)-conjugated anti-human CD56 mAb (clone B159,

mouse IgG<sub>1</sub>), anti-human β2-microglobulin (clone Tu99, mouse IgM), PE-conjugated anti-human intercellular adhesion molecule 1 (ICAM-1) mAb (clone HA58, mouse IgG<sub>1</sub>), and FITC-conjugated anti-Fas mAb from PharMingen (San Diego, CA, USA); and FITC-conjugated anti-human HLA class I molecule mAb (W6/32, clone B9.12.1, mouse IgG<sub>2a</sub>) from Immunotech (San Francisco, CA, USA). Hybridoma secreting mAb NE150 (clone NB-1, mouse IgG<sub>1</sub>) for CD56 (neural cell adhesion molecule, NCAM) was originally obtained from Dr. Takahashi (Aichi Cancer Center, Nagoya, Japan). NE150 was an ammonium sulfate precipitate of ascites, purified by protein A-Sepharose affinity chromatography. The NE150 F(ab')<sub>2</sub> fragments were prepared using Pierce ImmunoPure Fab Preparation Kit (Pierce Biotechnology Inc., Rockford, IL, USA).

**Flow cytometry.** Cells were incubated with each mAb and control mAb for 30 min at 4°C and were washed three times with phosphate-buffered saline (PBS) containing 0.2% FBS and 0.01% azide. For W6/32 and Tu99 mAbs, after washing, cells were incubated with FITC-conjugated F(ab')<sub>2</sub> fragment goat anti-mouse IgG Ab for 20 min at 4°C and were washed three times with PBS containing 0.2% FBS and 0.01% azide. Flow cytometry was performed on a FACScan (Becton Dickinson, CA, USA), and the data were analyzed with CellQuest software (Becton Dickinson). To

quantify the expression levels of HLA class I molecules, NCAM, LFA-3, ICAM-1, FAS, and  $\beta_2$ -microglobulin, the ratio of the mean fluorescence intensity (MFI) between test and control events was used (12). This ratio corresponded to the distance between the test and control MFI on a logarithmic scale. The expression levels of HLA class I molecules,  $\beta_2$ -microglobulin, adhesion molecules, and FAS were calculated as follows:  $10^{\log(\text{MFI tested})}/10^{\log(\text{control MFI})} = 10^{\log(\text{MFI tested}) - \log(\text{control MFI})}$ .

**Generation of effector cells.** Table I shows the characteristics of patients with SCLC treated at Okayama University Hospital. Recombinant human interleukin-2 (rhIL-2, TGP-3; Takeda Chemical Industries, Ltd. Japan) activated NK cells were generated from peripheral blood mononuclear cells (PBMNCs) of untreated patients with SCLC, which were prepared by Ficoll-Hypaque and purified using Mini-MACS system (NK cell Isolation Kit, Miltenyi Biotec K.K., Japan). CD56-positive cells represented over 95% of cells following the purification procedure (data not shown). Purified NK cells ( $1\text{--}1.5 \times 10^6/\text{ml}$ ) were cultured in RPMI-1640 supplemented with 10% FBS, non-essential amino acids, glutamine, sodium pyruvate,  $5 \times 10^{-5}$  M 2-mercaptoethanol, penicillin-G (100 U/ml), and streptomycin (100  $\mu\text{g}/\text{ml}$ ) (complete medium). A final concentration of 1000 U/ml rhIL-2 was added. On day 7, activated NK cells were used as effector cells.

**Cytotoxicity assay.** The prepared effector cells were first plated in 96-well, flat-bottomed, microplates in 150  $\mu\text{l}/\text{well}$  and kept at  $37^\circ\text{C}$  under humidified atmosphere with 5%  $\text{CO}_2$  in air prior to assay. Tumors cells as targets ( $1 \times 10^6$ ) were labeled with 100  $\mu\text{Ci}$  of sodium chromate ( $\text{Na}_2\text{CrO}_4$ ) at  $37^\circ\text{C}$  for 45 min. The labeled target cells were washed twice with ice-cold RPMI-1640 containing 5% FBS. Target cells were added to the effector cells at 5000 cells/well in 50  $\mu\text{l}$  immediately after the final wash. For cytotoxicity assay of tumor cells, several effector:target (E/T) ratios were used. The cytotoxicity test plates were incubated at  $37^\circ\text{C}$  under a humidified atmosphere with 5%  $\text{CO}_2$  in air for 4 h. After incubation, the plates were centrifuged at 2000 rounds per minute for 5 min. For accuracy of the assay, the upper half of the supernatant fluid was used to count the release of  $^{51}\text{Cr}$  using a gamma counter. The percentage of specific lysis was calculated as follows: % specific lysis =  $[(\text{release tested cpm} - \text{spontaneous release cpm}) / \text{total release cpm}] \times 100$ .

## Results

**Expression level of HLA class I molecules on SCLC cell lines.** Using flow cytometry, the expression of HLA class I molecules on SBC-7 cells was observed to be extremely low compared to those of lymphocytes from healthy volunteers or non-SCLC cells (Figure 1A). In addition, levels of HLA class I antigens and  $\beta_2$ -microglobulin in all SCLC cell lines were lower than those of lymphocytes from healthy volunteers (Figure 1B), which suggests that SCLC cells may be very susceptible to activated NK cells.

**Cytotoxicity of activated NK cells against SCLC cell lines.** Some previous reports had revealed that SCLC cells were sensitive to NK and lymphokine-activated killer (LAK) cells because HLA-class I antigen expression in SCLC cell lines was




Figure 1. A: Flow cytometric analysis of HLA class I molecules. The expression of HLA class I molecules on SBC-7 cells were extremely low compared with those of lymphocytes from healthy volunteers or non small-cell lung cancer cell lines (OU-LC-AS1 and EBC-2). B: Mean fluorescence intensity of HLA class I molecules and  $\beta_2$ -microglobulin by flow cytometric analysis. The expression levels of HLA class I molecules and  $\beta_2$ -microglobulin in all 11 small-cell lung cancer cell lines were extremely low compared with those of lymphocytes from healthy volunteers. H69: NCI-H69; Lu134: Lu-134-A-H; FM: RERF-LC-FM.

equally suppressed and NK and LAK cells do not receive negative signals through killer cell inhibitory receptor (KIR), such as p58 and p70, from down-regulating HLA class I molecules on SCLC cells (13, 14). Confirming this data, SCLC cells were found to be susceptible to activated NK cells generated from SCLC patients (Figure 2). Each SCLC cell line, except SBC-9a, was sensitive to activated NK cells and the NK-sensitive cell line K562. Moreover, activity against SCLC cell lines of NK cells from each patient differed in intensity.




Figure 2. Cytotoxicity of activated NK cells generated from SCLC patients against K562 and SCLC cell lines. Each SCLC cell line except SBC-9a as well as the cell line K562 were sensitive to lysis by activated NK cells.

**Relationship of adhesion molecules on SCLC cell lines and Cytotoxicity of NK cells towards SCLC cell lines.** A previous report described CD56 on NK cells as a third pathway of cell adhesion other than those mediated by CD2/LFA-3 and LFA-1/ICAM-1 interactions and that CD56 was involved in NK cell cytotoxicity when interacting with cells bearing CD56/NCAM (15). In this experiment, the expression of NCAM, however, did not predict activated NK cell cytotoxicity (Figures 2 and 3A). In addition, the cytotoxicity of activated NK cells towards NCAM-overexpressing SBC-7 cells was not blocked even when anti-NCAM F(ab')<sub>2</sub> mAb was added (Figure 4). Hence, we do not presume that NCAM-NCAM interaction mediated NK cell cytotoxicity towards SCLC cell lines. Differences in target cell susceptibility to activated NK cells showed no correlation with the expression level of HLA class I molecules, ICAM-1, or LFA-3 (16). We confirmed this finding that target cell susceptibility of activated NK cells showed no correlation with the expressions of ICAM-1, LFA-3, and FAS (Figure 3B).

**Relationship of cytotoxicity towards SCLC cell lines and patient survival.** Activated NK cells generated from patients 4 and 5 showed that the percentage specific <sup>51</sup>Cr-release was >40% in 10 out of 11 SCLC cell lines (Figure 2). These patients have survived more than 4 years without relapse. Activated NK cells generated from patients 2 and 3 showed that the percentage specific <sup>51</sup>Cr-release was ≤40% in all 11 SCLC cell lines, and <sup>51</sup>Cr-release of patient 1 was ≤40% in 9 out of 11 SCLC cell lines (Figure 2). These patients all experienced disease relapse and died.

## Discussion

In this experiment, activated NK cells efficiently killed SCLC cells with a very low level of expression of HLA class I molecules. Furthermore, we confirmed previous data that target cell susceptibility to activated NK cells showed no correlation with the expressions of surface adhesion molecules. Target cell susceptibility to activated NK cells is very complex. Although the use of LAK cells has been intensively studied, this approach has not consistently shown benefits in clinical trials (17). Recent basic studies have shown that NK cells have a variety of receptors that recognize class I molecules. NK cell cytotoxicity is controlled by the balance between KIR and killer-cell activating receptor (KAR). NK cells can kill the allografts that are lacking one or more self-class I molecules because no negative signals are transmitted to a particular subset of NK cells through KIR (18). Several reports have shown that HLA-class I molecule expression levels in lung cancer cell lines are reduced and these molecules are susceptible to lysis by NK and LAK cells (12, 13).

In high-dose chemotherapy treatments with AHSCT, peripheral blood stem cells (PBSCs) contain more NK cells than do bone marrow aspirates (19). If these NK cells are effectively activated, contaminating tumor cells in PBSCs should be eradicated. Thus, we assume that a very small number of SCLC cells are susceptible to lysis by NK cells or activated NK cells. Even recent and very intensive therapy will be unable to eradicate all tumor cells. Presumably, between 10<sup>5</sup> and 10<sup>6</sup>





Figure 3. Expression of neural cell adhesion molecule (NCAM) (A) and Expression of intercellular adhesion molecule (ICAM), lymphocyte function-associated antigen-3 (LFA-3) and Fas/Apo-1 receptor (Fas) (B) on small-cell lung cancer cells by flow cytometric analysis.

tumor cells remain even in complete responders. If complete responders achieve a cure, minimal residual SCLC cells are eradicated efficiently by NK cells or activated NK cells.

Strong cytotoxicity of activated NK cells against SCLC cell lines may be linked to patients' immune status after intensive treatment. In our results, patients with specific




Figure 4. Effects of anti-CD56 F(ab')<sub>2</sub> mAb on cytotoxicity of activated natural killer (NK) cells against K562 and SBC-7 cells. The cytotoxicity of activated NK cells on neural cell adhesion molecule (NCAM)-overexpressing SBC-7 cells was not blocked even when anti-NCAM F(ab')<sub>2</sub> mAb was added.

<sup>51</sup>Cr-release >40% in 10 out of 11 SCLC cell lines have survived without disease and are working full-time. However, patients with specific <sup>51</sup>Cr-release ≤40% in the majority of the SCLC cell lines experienced disease relapse and died. This result indicates that target cell susceptibility to activated NK cells from patients with SCLC may correlate with favorable clinical outcomes. In other words, the target cell susceptibility to activated NK cells may be a surrogate marker of clinical outcome of SCLC patients. Clinical trials of high-dose chemotherapy with AHSCT and the use of LAK cells have not consistently shown an apparent benefit in unselected SCLC patients. However, these modalities could be one of the standard treatments if the benefits were proven in clinical trials in selected SCLC patients using target cell susceptibility to activated NK cells.

In conclusion, since the cytotoxicity of activated NK cells towards SCLC cell lines may be linked to the immune state after intensive treatment, SCLC patients achieving a complete response should be exposed to a promoter of NK activity. Prospective trials will be essential to elucidate the role of NK cells or activated NK cells prior to adopting new treatments.

## Acknowledgements

We thank Masahiro Tabata, Hiroshi Ueoka and Mine Harada, Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, for helpful comments and discussion during drafting of this report.

# References

- 1 Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. *CA Cancer J Clin* 59: 225-249, 2009.
- 2 Hanna N, Bunn PA Jr., Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B and Sandler A: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive stage disease small-cell lung cancer. *J Clin Oncol* 24: 2038-2043, 2006.
- 3 van Meerbeeck JP, Fennell DA and De Ruysscher DK: Small-cell lung cancer. *Lancet* 378(9804): 1741-1755, 2011.
- 4 Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F and Nukiwa T: Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. *J Clin Oncol* 26(33): 5401-5406, 2008.
- 5 Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH and Frei E 3rd: Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. *J Clin Oncol* 17: 1175-1184, 1999.
- 6 Elias AD, Skarin AT, Richardson P, Ibrahim J, McCauley M and Frei E 3rd: Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. *Biol Blood Marrow Transplant* 8: 326-333, 2002.
- 7 Costanzo R, Piccirillo MC, Sandomenico C, Carillio G, Montanino A, Daniele G, Giordano P, Bryce J, De Feo G, Di Maio M, Rocco G, Normanno N, Perrone F and Morabito A: Gefitinib in non small cell lung cancer. *J Biomed Biotechnol* 2011: 815269, 2011.
- 8 Rossi A, Garassino MC, Cinquini M, Sburlati P, Di Maio M, Farina G, Gridelli C and Torri V: Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. *Lung Cancer* 70(2): 119-128, 2010.
- 9 Payne D, Burkes R and Ginsberg RJ: Chapter 17. Lung Cancer. In: *UICC manual of clinical oncology*. 8th ed. Pollock RE, Doroshow JH, Khayat D, Nakao A and O'Sullivan B (eds.). Hoboken, New Jersey, Wiley Liss, pp. 381-403, 2004.
- 10 Kawai H, Kiura K, Tabata M, Yoshino T, Takata I, Hiraki A, Chikamori K, Ueoka H, Tanimoto M and Harada M: Characterization of non-small cell lung cancer cell lines established before and after chemotherapy. *Lung Cancer* 35: 305-314, 2002.
- 11 Hiraki A, Kaneshige T, Kiura K, Ueoka H, Yamane H, Tanaka M and Harada M: Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. *Clin Cancer Res* 5: 933-936, 1999.
- 12 Hiraki A, Fujii N, Murakami T, Kiura K, Aoe K, Yamane H, Masuda K, Maeda T, Sugi K, Darzynkiewicz Z, Tanimoto M and Harada M: High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines. *Anticancer Res* 24: 1525-1528, 2004.
- 13 Tanio Y, Watanabe M, Osaki T, Tachibana I, Kawase I, Kuritani T, Saito S, Masuno T, Kodama N, Furuse K and Kishimoto T: High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity. *Jpn J Cancer Res* 83: 736-745, 1992.
- 14 Lagadec PF, Saraya KA and Balkwill FR: Human small-cell lung cancer cells are cytokine-resistant but NK/LAK-sensitive. *Int J Cancer* 48: 311-317, 1991.
- 15 Nitta T, Yagita H, Sato K and Okumura K: Involvement of CD56 (NKH-1/Leu-19 antigen) as an adhesion molecule in natural killer target cell interaction. *J Exp Med* 170: 1757-1761, 1989.
- 16 Lehmann C, Glass B, Zeis M, Schmitz N and Uharek L: Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK cell-mediated cytotoxicity. *Cancer Immunol Immunother* 48: 209-213, 1999.
- 17 Yamaguchi Y, Ohshita A, Kawabuchi Y, Ohta K, Shimizu K, Minami K, Hihara J, Miyahara E and Toge T: Adoptive immunotherapy of cancer using activated autologous lymphocytes-current status and new strategies. *Hum Cell* 16: 183-189, 2003.
- 18 Purdy AK and Campbell KS: Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). *Cancer Biol Ther* 8: 2211-2220, 2009.
- 19 Majolino I, Cavallaro AM and Scimè R: Peripheral blood stem cells for allogeneic transplantation. *Bone Marrow Transplant* 18(2): 171-174, 1996.

Received January 20, 2012

Revised February 16, 2012

Accepted February 17, 2012



